Roivant Sciences Ltd.
ROIVHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Roivant Sciences Ltd. focuses on Biotechnology services and products. Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. The company carries a $26.36B market cap, placing it firmly in the large-cap category. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases.
Market Cap
$26.36B
Beta
1.10
P/E (TTM)
—
P/E (Fwd)
-21.24
EPS (TTM)
$-0.53
EPS (Fwd)
$-1.72
ROE
-8.5%
ROA
-16.3%
Cash
$3.84B
Total Debt
$107.2M
Free CF
-$1.12B
52W Change
94.0%
Annual Financials
Cash vs Debt
Where ROIV stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, ROIV finished 2.66% above its 150-day moving average ($32.66) and 8.90% above its 200-day moving average ($30.79). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ROIV overbought or oversold?
At the October 19, 2026 close, ROIV's RSI(14) was 28.4, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $3.84B in cash comfortably exceeding the $107.2M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$1.12B, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -8.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $31.5M (2023) to $8.3M (2026), a 74% decline worth watching.
With cash comfortably exceeding debt, ROIV has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Roivant Sciences Ltd. and its sector.